Marwa Aly | Bacterial Extracellular Vesicles | Best Researcher Award

Published on by Cell Biologist

Dr. Marwa Aly | Bacterial Extracellular Vesicles | Best Researcher Award

Dr. Marwa Aly | HB Fuller | United States

Dr. Marwa Aly (published as Marwa Gamal Saad), Ph.D., is a Senior Scientist at H.B. Fuller Company with an impressive interdisciplinary background spanning microbiology, bioengineering, nanotechnology, and biotechnology. She holds dual Ph.D. degrees from Port Said University (with research at Texas A&M University) and Washington State University, where she recently completed a thesis on bacterial extracellular vesicles targeting drug-resistant pathogens. Dr. Aly has authored multiple high-impact publications, secured substantial research funding, and contributed to patent-pending technologies. Her innovative work bridges the gap between microbial research and real-world applications, such as alternative biofuels and novel antimicrobials. With an h-index of 6 and over 250 citations, she has demonstrated consistent scientific impact. Recognized by prestigious awards like the Cougar Cage Award and WSU President’s Leadership Award, Dr. Aly is an emerging thought leader in microbial biotechnology, making her a prime candidate for the Best Researcher Award.

Publication Profiles:

Google Scholar
Scopus
Orcid

Education:

Dr. Marwa Aly holds two Doctor of Philosophy degrees in advanced scientific disciplines. She earned her first Ph.D. in Botany from Port Said University, Egypt, with collaborative research at Texas A&M University, USA. Her research focused on sustainable biofuel production from microalgae using nanotechnology and genetic engineering. She recently completed a second Ph.D. in Engineering from Washington State University, USA. Her dissertation investigated bacterial extracellular vesicles and their potential as next-generation antimicrobials against drug-resistant pathogens. Dr. Aly’s dual doctoral qualifications reflect her interdisciplinary expertise and commitment to solving complex global challenges. Her educational journey is marked by innovation, academic rigor, and successful translation of research into real-world impact.

Research Experience:

As a Graduate Assistant at Washington State University in Dr. Wen-Ji Dong’s Lab, Dr. Aly has pioneered research on microbial extracellular vesicles (EVs), securing a provisional patent and winning $100,000 in Cougar Cage funding. Her work involves in vitro and in vivo analysis of EVs from Pseudomonas aeruginosa, exploring their antimicrobial action, especially against Candida auris and drug-resistant pathogens. She also studies the role of ferroptosis in EV-mediated treatment strategies and has led proteomic profiling of bacterial biofilms. In her earlier Ph.D. work, she developed methods for microalgae-based biodiesel production using advanced microfluidics and nanotechnology. Her multidisciplinary research blends microbiology, chemical engineering, and biotechnology to address critical challenges in public health and sustainable energy. Her scientific contributions are recognized globally, making her a strong contender for research excellence.

Awards and Honors:

Dr. Marwa Aly has received multiple prestigious accolades recognizing her leadership, innovation, and research excellence. She was a winner of the ISEV Image Competition, celebrating creativity in extracellular vesicle research. She received the Cougar Cage Award from Washington State University for her promising EV-based antimicrobial proposal. Her leadership and academic excellence earned her the WSU President’s Award for Leadership and recognition as a WSU Woman of Distinction. These awards highlight not only her scientific contributions but also her dedication to community engagement, mentorship, and cross-disciplinary collaboration. Her ability to secure competitive funding, publish impactful research, and innovate at the intersection of biology and engineering underscores her qualifications for the Best Researcher Award.

Research Focus:

Dr. Marwa Aly’s research centers on extracellular vesicles (EVs) and their potential to combat antimicrobial resistance. Her recent focus is on stage-dependent EVs produced by Pseudomonas aeruginosa and algae, exploring their ability to disrupt biofilms and trigger ferroptosis in pathogenic organisms. Her research includes proteomic analysis, biofilm interaction studies, and in vivo wound infection models, advancing the understanding of EVs as therapeutic agents. Additionally, she has conducted microfluidic-based studies for biofuel optimization, developing innovative devices to study microalgae growth under various environmental conditions. Her work is grounded in translational science, bridging lab discoveries with industrial applications such as bioenergy and infection control. By integrating microbiology, bioengineering, and nanotech, she is at the forefront of next-generation biotechnologies, making substantial contributions to public health, sustainability, and microbial sciences.

Publications Top Notes:

  1. Algal Biofuels: Current Status and Key Challenges – Energies

  2. Exosomes as Powerful Engines in Cancer: Isolation, Characterization and Detection Techniques – Biosensors

  3. Evaluation of Storage Stability for Biocrude Derived from Hydrothermal Liquefaction of Microalgae – Energy & Fuels

  4. High-Throughput Screening of Chlorella Vulgaris Growth Kinetics in Microfluidics – Biomolecules

  5. Droplet-based Microfluidic Gradient for Chlorella Growth under Nitrogen & Temp Stress – Algal Research

  6. Impact of Nitrogen Regime on Fatty Acid Profiles of Algae for Biofuel – Acta Botanica Hungarica

  7. Dual Roles of Conditional Extracellular Vesicles from Pseudomonas Biofilms – Biofilm

  8. Phytochemical Screening and Antimicrobial Activity of Egyptian Green Algae – Journal of Medicinal Plants Studies

  9. Nitrogen Concentration Impact on Algal Biomass, Lipids & Biofuel Yield – IJSTR

  10. Challenges of Biodiesel Production from Oscillatoria sp. – IJAR

Conclusion:

In conclusion, Dr. Marwa Aly (Marwa Gamal Saad) is a highly qualified, driven, and impactful researcher who has made significant contributions across several vital scientific areas, from microbial therapeutics to renewable biofuels. Her dual-Ph.D. credentials, publication record, patent-pending research, competitive grant success, and multiple recognitions make her an excellent candidate for the Best Researcher Award. While she can further enhance her profile through increased international engagement and publication output, her current achievements already distinguish her as a rising leader in the fields of biotechnology, microbiology, and bioengineering. She is not only suitable but highly recommended for this recognition.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.